Fig. 1.

(A) Schema for animal survival experiments. Irradiated autologous GL261 cells expressing GM-CSF were injected subcutaneously on days 3, 6, and 9 after intracranial implantation of tumor cells, synchronously with intraperitoneal injection of anti-OX40 antibody. (B) Animals treated with combination GVAX and anti-OX40 antibody lived significantly longer than animals receiving either as monotherapy. Animals from both GVAX and anti-OX40 monotherapy groups lived significantly longer than control-treated mice. (****P < 0.00005, ***P < 0.0005, **P < 0.005; absence of an asterisk denotes not significant comparison.)